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Diagnostic performances 
and unnecessary US‑fnA rates 
of various tiRADS after application 
of equal size thresholds
Sun Huh1, Hye Sun Lee2, Jiyoung Yoon1, eun‑Kyung Kim1, Hee Jung Moon1, Jung Hyun Yoon1, 
Vivian Youngjean park1 & Jin Young Kwak1*
We compared the diagnostic performances and unnecessary fnA rates of several guidelines and 
modified versions using the size threshold of the ACR TIRADS. Our Institutional Review Board 
approved this retrospective study and waived the requirement for informed consent and all methods 
were performed in accordance with the Declaration of Helsinki. A total of 1,384 thyroid nodules in 
1,301 patients with definitive cytopathologic findings were included. US categories were assigned 
according to each guideline. We applied the size threshold suggested by the ACR TIRADS for FNA 
to the Kwak, ATA and EU guidelines and defined these modified guidelines as the modified Kwak 
(mKwak), modified ATA (mATA) and modified EU (mEU) guidelines. Diagnostic performances and 
unnecessary FNA rates of all guidelines were evaluated. Of 1,384 thyroid nodules, 291 (21%) were 
malignant. Among the original guidelines, the ACR TIRADS had the highest specificity, accuracy, 
LR and AUC (62.2%, 66%, 2.128 and 0.713). The mKwak, mATA and mEU guidelines had higher 
specificity, accuracy, LR and AUC (P < 0.001 for all), and fewer unnecessary FNAs, compared with their 
original guidelines. Among all original and modified guidelines, the mKwak guideline had the highest 
specificity, accuracy, LR and AUC (64%, 68.6%, 2.389 and 0.75). The unnecessary FNA rate was the 
lowest with the mKwak guideline (61.1%). The highest sensitivity was observed with the ATA guideline 
(98.6%). After incorporating the size threshold of the ACR TIRADS to other TIRADS, all guidelines 
showed higher diagnostic accuracy and lower unnecessary FNA rates than their original versions. The 
mKwak guideline showed the best diagnostic performances.
Thyroid ultrasonography (US) is now regularly performed in clinical practice and thyroid nodules are exceedingly 
common on US with as many as 68% of adults having one, leading to issues of overdiagnosis and  overtreatment1,2. 
Many guidelines recommend fine-needle aspiration (FNA) based on several risk stratification systems which use 
different US features and even different size  thresholds3–7. Current risk stratification systems using US features can 
be broadly divided into two types: the point-scale Thyroid Imaging Reporting and Data System (TIRADS) sug-
gested by Kwak et al. 8, Park et al. 9 and the American College of Radiology (ACR)3 and the pattern-recognition 
TIRADS suggested by Horvath et al. 10, the 2015 American Thyroid Association (ATA)7, and European Thyroid 
Association (EU)11. Different size criteria have been suggested by the ATA guideline, ACR and EU  TIRADS3,7,11. 
Although there are many guidelines for recommending FNA for thyroid nodules on US, a worldwide commu-
nicable system does not presently exist.
Recently, Grani et al. 12 demonstrated that the ACR TIRADS reduced unnecessary FNAs more than other 
international guidelines with a very low false-negative rate (2.2%, 6/268). The ACR TIRADS suggests a higher 
size threshold for FNA than other guidelines while still recommending similar malignancy risks for each final 
assessment  category3,7,11, and this higher size threshold is thought to explain the decrease in unnecessary  FNAs3. 
However, physicians may need more time to classify a nodule on US when using the ACR TIRADS because 
each US feature is weighted  differently3. On the other hand, one of other point-scale risk stratification systems 
open
1Department of Radiology, Research Institute of Radiological Science, and Center for Clinical Imaging Data 
Science, Yonsei University College of Medicine, Seoul, Korea. 2Biostatistics Collaboration Unit, Yonsei University 
College of Medicine, Seoul, Korea. *email: docjin@yuhs.ac
2
Vol:.(1234567890)
Scientific RepoRtS |        (2020) 10:10632  | https://doi.org/10.1038/s41598-020-67543-z
www.nature.com/scientificreports/
proposed by Kwak et al. (Kwak TIRADS) has been proven to be practical and easily applicable in the assessment 
of thyroid  nodules8,13–20, and can be performed by simply counting the number of suspicious US features without 
considering the malignancy probability of each US feature. One recent study compared the diagnostic efficiency 
of Kwak and ACR TIRADS and found the former to have higher AUC and  accuracy19. However, the study did 
not consider the size threshold for recommending  FNA19. We assumed that if they have similar diagnostic 
performances with the same size threshold for thyroid nodules, radiologists and clinicians can choose the more 
convenient risk stratification system for daily practice.
To find an effective guideline for recommending FNA for thyroid nodules, we investigated the diagnostic 
performances and unnecessary FNA rates of several guidelines in their original form, and their modified versions 
using the size threshold proposed by the ACR TIRADS.
Results
Baseline clinicopathological characteristics. Of 1,384 thyroid nodules, 1,093 (79%) were benign and 
291 (21%) were malignant (Fig. 1, Table 1). 397 nodules (28.7%) underwent surgery, 10 nodules (0.7%) were 
diagnosed by core needle biopsy and the last 977 (70.6%) nodules were diagnosed by cytologic findings from 
FNA. Among the 397 nodules which underwent surgery, 264 (66.5%, 264/397) were diagnosed as malignant and 
133 (33.5%, 133/397) as benign. The malignant nodules were comprised of 234 papillary thyroid carcinomas 
(197 conventional, 33 follicular, 2 solid, 1 columnar and 1 oncocytic variant), 21 minimally invasive follicular 
carcinomas, 5 medullary carcinomas, 3 anaplastic carcinomas and 1 metastatic nasopharyngeal carcinoma. The 
most frequently excised benign nodules were follicular adenoma (n = 70) followed by adenomatous hyperpla-
sia (n = 59), Hurthle cell adenoma (n = 3), and fibrotic nodule (n = 1). Demographics and US features of the 
patients and nodules are summarized in Table 1. The mean age (mean 51.1 ± 13.4; range, 18–90) was signifi-
cantly higher in patients with benign nodules than patients with malignant nodules (mean 47 ± 13.7 years; range, 
18–85 years) (P < 0.001). Malignant thyroid nodules were significantly smaller than benign nodules (mean diam-
eter 20.3 ± 12.9 mm and 24 ± 12.3 mm, respectively) (P < 0.001). The malignant thyroid nodules had significantly 
higher rates of solid composition, hypoechogenicity or marked hypoechogenicity, microlobulated or irregular 
margins, microcalcifications or mixed calcifications, and nonparallel shape than benign nodules (P < 0.001 for 
all).
Malignancy rates according to categories in the risk stratification systems. Each risk stratifica-
tion system had significantly different malignancy rates according to categories (Table 2, P < 0.001 for all). Most 
of the categorized lesions according to ACR and EU TIRADS were all in the range of the recommended risks of 
malignancy except for the not suspicious lesions (category 2) of ACR TIRADS and low risk (category 3) lesions 
of EU TIRADS. All categories except nodules of intermediate suspicion (category 4) in the ATA guideline were 
outside the recommended range.
Diagnostic performances of the guidelines. Among the original guidelines we evaluated, the ACR 
TIRADS had highest specificity, accuracy, LR and AUC (62.2%, 66%, 2.128 and 0.713, respectively) (P < 0.001 
for all, Tables 3 and 4, Figs. 2 and 3) followed by Kwak guideline (35%, 47.5%, 1.458 and 0.649, respectively), 
EU guideline (28.1%, 42.2%, 1.324 and 0.616, respectively) and ATA guideline (19.9%, 36.4%, 1.231 and 0.592, 
respectively). Sensitivity was the highest with the ATA guideline (98.6%) and the lowest with the ACR guideline 
(80.4%, P = 0.011 comparing ATA and Kwak, P = 0.001 comparing the ATA and EU guidelines, P < 0.001 for the 
other guidelines).
Figure 1.  Diagram of the study cohort. FNA fine-needle aspiration, US ultrasonography.
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When the size threshold of ACR TIRADS was applied to the original TIRADS, the diagnostic ability increased 
in terms of specificity, accuracy, LR and AUC for all guidelines (Tables 3 and 4, Figs. 2 and 3). The modified 
Kwak (mKwak) guideline had a specificity of 64%, accuracy of 68.6%, LR of 2.389 and AUC of 0.75 while the 
Kwak guideline had a specificity of 35%, accuracy of 47.5%, LR of 1.458 and AUC of 0.649 (P < 0.001 for all). The 
modified ATA (mATA) guideline had a specificity of 57.2%, accuracy of 63.2%, LR of 1.998 and AUC of 0.714, 
while the original ATA guideline had a specificity of 19.9%, accuracy of 36.4%, LR of 1.231 and AUC of 0.592 
(P < 0.001 for all). The modified EU (mEU) guideline had a specificity of 40.1%, accuracy of 51.4%, LR of 1.565 
and AUC of 0.669, while the EU guideline had a specificity of 28.1%, accuracy of 42.2%, LR of 1.324 and AUC 
of 0.616 (P < 0.001 for all). However, the sensitivities of the modified guidelines were lower than their original 
versions. The sensitivity of the original guidelines was 94.8%, 98.6%, 95.2% for the Kwak, ATA and EU guidelines, 
respectively, while the modified versions showed a sensitivity of 85.9%, 85.6% and 93.8% for the mKwak, mATA 
and mEU guidelines, respectively. Among all the original and modified guidelines, the mKwak guideline had 
the highest specificity, accuracy, LR and AUC (64%, 68.6%, 2.389 and 0.75, respectively) (P = 0.014 comparing 
the specificity of with ACR and P < 0.001 for the others).
The unnecessary FNA rate was the lowest with the mKwak guideline (61.1%, 393/643) followed by the ACR 
(63.8%, 413/647), mATA (65.3%, 468/717), mEU (70.6%, 655/928), Kwak (72%, 711/987), EU (73.9%, 786/1,063) 
and ATA guidelines (75.3%, 876/1,163) (Table 5, Fig. 3). In all modified guidelines, the unnecessary FNA rate 
decreased comparing to the original guidelines when the size threshold of the ACR TIRADS was applied.
Discussion
Currently, many guidelines composed of various TIRADS and size thresholds exist for further work-up such as 
FNA or follow-up  US3,4,7,11. However, there has been no proven universal guideline proposed to reduce unneces-
sary FNAs and to find as many thyroid cancers as possible. It has also been difficult to compare the risk stratifica-
tion systems themselves as each uses a different size threshold to recommend FNA although many studies have 
compared the diagnostic performances and unnecessary FNA rates of these  guidelines12,20–25. To overcome this 
problem, we applied the size threshold of the ACR guideline to the Kwak, ATA and EU guidelines by matching 
Table 1.  Demographics of patients and nodules. Data in parentheses are percentages. SD standard deviation.
Final pathology
Total Malignancy rate P valueBenign (n = 1,093) Malignant (n = 291)
No. of nodules 1,093 (79) 291 (21) 1,384
No. of patients 1,024 (78.7) 277 (21.3) 1,301
Age  < 0.001
 Mean ± SD 51.1 ± 13.4 47 ± 13.7 50.2 ± 13.6
 Range 18–90 18–85 18–90
Sex 0.111
 Men 179 (17.5) 60 (21.7) 239 (18.4)
 Women 845 (82.5) 217 (78.4) 1,062 (81.6)
Size  < 0.001
 Mean ± SD 24 ± 12.3 20.3 ± 12.9 23.2 ± 12.6
 Range 10–100 10–70 10–100
US feature
Composition  < 0.001
 Solid 554 (50.7) 252 (86.6) 806 (58.2) 31.27 (1.7)
 Predominantly solid 417 (38.2) 35 (12) 452 (32.7) 7.74 (1.3)
 Predominantly cyst 122 (11.2) 4 (1.4) 126 (9.1) 3.18 (1.6)
Echogenicity  < 0.001
 Marked hypoechoic 18 (1.7) 36 (12.4) 54 (3.9) 66.67 (6.6)
 Hypoechoic 370 (33.9) 206 (70.8) 576 (41.6) 35.76 (2.1)
 Iso- to hyperechoic 705 (64.5) 49 (16.8) 754 (54.5) 6.5 (1)
Margin  < 0.001
 Well 939 (85.9) 83 (28.5) 1,022 (73.8) 8.12 (0.9)
 Microlobulated or irregular 154 (14.1) 208 (71.5) 362 (26.2) 57.46 (2.7)
Calcification  < 0.001
 Negative 909 (83.2) 119 (40.9) 1,028 (74.3) 11.58 (1.1)
 Macro or eggshell 135 (12.4) 35 (12) 170 (12.3) 20.59 (3.2)
 Micro or mixed 49 (4.5) 137 (47.1) 186 (13.4) 73.66 (3.3)
Shape  < 0.001
 Parallel 1,044 (95.5) 178 (61.2) 1,222 (88.3) 14.57 (1.1)
 Nonparallel 49 (4.5) 113 (38.8) 162 (11.7) 69.75 (3.7)
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the recommended malignancy rates. After applying the ACR TIRADS size threshold in the modified guidelines, 
diagnostic ability increased in terms of specificity, accuracy, LR and AUC compared with the original guide-
lines and the unnecessary FNA rates were also lower. The mKwak guideline which incorporated the ACR size 
threshold showed the best diagnostic results among the original and modified guidelines in terms of specificity, 
accuracy, LR and AUC.
Recently, many researchers demonstrated that the ACR TIRADS had superior diagnostic performance com-
pared to other guidelines and reduced larger number of unnecessary FNAs (compared with guidelines from 
ATA, EU, American Association of Clinical Endocrinologists/American College of Endocrinology/Associazione 
Medici Endocrinologi, National Comprehensive Cancer Network, French Society of Endocrinology, Society of 
Radiology in Ultrasound and Korean Thyroid Association/Korean Society of Thyroid)12,21–23,25. Considering that 
the ACR incorporates a larger size threshold for FNA despite using similar recommended malignancy risks, the 
better diagnostic ability of the ACR guidelines can be explained by the size criteria for FNA and not the compli-
cated US risk stratification system  itself26. In this study, the ACR guideline showed better diagnostic accuracy 
than the original Kwak guideline which uses a 10 mm size threshold to recommend US-guided FNA (US-FNA) 
regardless of the number of suspicious US features. However, the mKwak guideline showed higher diagnostic 
Table 2.  Comparison of Malignancy Rates with Several Risk Stratification Systems. Data in parentheses 
are percentages. ACR American College of  Radiology3, Kwak Kwak et al.’s  study8, ATA American Thyroid 
 Association7, EU European Thyroid  Association11.
Category
Final diagnosis
P value Calculated risk of malignancy (%)
Recommended risk of 
malignancy (%)Benign (n = 1,093) Malignant (n = 291)
ACR 
2—not suspicious 355 (32.5) 15 (5.2)  < 0.001 4.1 2
3—mildly suspicious 337 (30.8) 16 (5.5) 4.5 5
4—moderately suspicious 318 (29.1) 66 (22.7) 17.2 5–20
5—highly suspicious 83 (7.6) 194 (66.7) 70  ≥ 20
Kwak
3—no suspicious US feature 382 (35) 15 (5.2)  < 0.001 3.8
4a—one suspicious US feature 387 (35.4) 21 (7.2) 5.2
4b—two suspicious US features 201 (18.4) 41 (14.1) 16.9
4c—three or four suspicious US 
features 116 (10.6) 160 (55) 58
5—five suspicious US features 7 (0.6) 54 (18.6)  < 0.001 89
ATA 
2—very low suspicion 485 (44.4) 20 (6.9) 4  < 3
3—low suspicion 260 (23.8) 13 (4.5) 4.8 5–10
4—intermediate suspicion 215 (19.7) 52 (17.9) 19.5 10–20
5—high suspicion 133 (12.2) 206 (70.8) 60.8  > 70–90
EU
3—low risk 642 (58.7) 28 (9.6)  < 0.001 4.2 2–4
4—intermediate risk 247 (22.6) 33 (11.3) 11.8 6–17
5—high risk 204 (18.7) 230 (79) 53 26–87
Table 3.  Diagnostic Performances of the Four Guidelines and their Modified Guidelines. Number in 
parentheses are 95% confidence intervals. Numbers in brackets are raw data. NPV negative predictive value, 
PPV positive predictive value, LR likelihood ratio, AUC area under the receiver operating characteristic curve, 
ACR American College of  Radiology3, Kwak Kwak et al.’s  study8, ATA American Thyroid  Association7, EU 
European Thyroid  Association11. *The modified Kwak (mKwak), modified ATA (mATA) and modified EU 
(mEU) guidelines incorporated the size threshold suggested by the ACR guideline.
Sensitivity Specificity Accuracy PPV NPV LR AUC 








[680/737] 2.128 (1.935–2.34) 0.713 (0.686–0.74)








[382/397] 1.458 (1.385–1.534) 0.649 (0.63–0.668)








[700/741] 2.389 (2.18–2.619) 0.75 (0.725–0.774)








[217/221] 1.231 (1.191–1.271) 0.592 (0.579–0.606)








[625/667] 1.998 (1.839–2.172) 0.714 (0.689–0.739)








[307/321] 1.324 (1.265–1.385) 0.616 (0.598–0.635)








[438/456] 1.565 (1.479–1.657) 0.669 (0.649–0.69)
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Table 4.  Comparison of Diagnostic Performances of the Four Guidelines and their Modified Guidelines. 
NPV negative predictive value, PPV positive predictive value, LR likelihood ratio, AUC area under the receiver 
operating characteristic curve, ACR American College of  Radiology3, Kwak Kwak et al.’s  study8, ATA American 
Thyroid  Association7, EU European Thyroid  Association11. *The modified Kwak (mKwak), modified ATA 
(mATA) and modified EU (mEU) guidelines incorporated the size threshold suggested by the ACR guideline.
P value
Sensitivity Specificity Accuracy PPV NPV LR AUC 
ACR vs Kwak  < .001  < .001  < .001  < .001  < .001  < .001  < .001
ACR vs mKwak*  < .001 0.014  < .001  < .001  < .001  < .001  < .001
ACR vs ATA  < .001  < .001  < .001  < .001  < .001  < .001  < .001
ACR vs mATA* 0.008  < .001 0.009 0.117  < .001 0.115 0.958
ACR vs EU  < .001  < .001  < .001  < .001 0.002  < .001  < .001
ACR vs mEU*  < .001  < .001  < .001  < .001  < .001  < .001  < .001
Kwak vs mKwak  < .001  < .001  < .001  < .001 0.028  < .001  < .001
Kwak vs ATA 0.011  < .001  < .001  < .001 0.132  < .001  < .001
Kwak vs mATA  < .001  < .001  < .001  < .001 0.003  < .001  < .001
Kwak vs EU 0.853  < .001  < .001 0.006 0.693 0.006  < .001
Kwak vs mEU 0.59 0.008 0.015 0.055 0.894 0.055  < .001
mKwak vs ATA  < .001  < .001  < .001  < .001  < .001  < .001  < .001
mKwak vs mATA 0.808  < .001  < .001  < .001 0.181  < .001  < .001
mKwak vs EU  < .001  < .001  < .001  < .001 0.211  < .001  < .001
mKWak vs mEU  < .001  < .001  < .001  < .001 0.027  < .001  < .001
ATA vs mATA  < .001  < .001  < .001  < .001  < .001  < .001  < .001
ATA vs EU 0.001  < .001  < .001  < .001 0.011  < .001 0.001
ATA vs mEU  < .001  < .001  < .001  < .001 0.021  < .001  < .001
mATA vs EU  < .001  < .001  < .001  < .001 0.088  < .001  < .001
mATA vs mEU  < .001  < .001  < .001  < .001 0.02  < .001 0.001
EU vs mEU 0.044  < .001  < .001  < .001 0.451  < .001  < .001
Figure 2.  Receiver operating characteristic curves of the four guidelines and their modified guidelines. The 
modified Kwak (mKwak), modified ATA (mATA) and modified EU (mEU) guidelines incorporated the size 
threshold suggested by the ACR guideline. ACR American College of  Radiology3, Kwak Kwak et al.’s  study8, ATA 
American Thyroid  Association7, EU European Thyroid  Association11.
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accuracy than the original ACR guideline after the size threshold of the ACR guideline was applied. When US 
risk stratification systems are compared between the ACR and Kwak guidelines, the Kwak guideline is more 
straightforward and practical to use than the ACR guideline which uses a different point system for individual 
US features as they are assigned different  weights3,8. Therefore, a combination of the easier US risk stratification 
system of the Kwak guideline and the size threshold of the ACR guideline can help clinicians in daily practice.
Increasing the size threshold of US-FNA resulted in decreasing the unnecessary FNA rate in all the guidelines 
we evaluated, which was the trade-off for lower sensitivity. In our study, the unnecessary FNA rate decreased 
more than sensitivity did for both the Kwak and EU guidelines. Size modification reduced the unnecessary 
FNA rate of the Kwak and EU guidelines by 10.9% and 3.3%, respectively while reducing sensitivity by 8.9% and 
1.4%, respectively. When the ATA and mATA guidelines were compared, sensitivity decreased by 13% and the 
unnecessary FNA rate decreased by 10% with the mATA guidelines. As the only difference between the modified 
and original guidelines was size criteria, we can assume that the size threshold proposed by the ACR guideline 
increased diagnostic accuracy and reduced the unnecessary FNA rates. In one recent study, diagnostic perfor-
mance and the unnecessary biopsy rate were evaluated with simulations using various nodule size cutoffs applied 
to the ATA and Korean Thyroid Association/Korean Society of Thyroid Radiology guidelines (KTA/KSThR)22. 
Among the various simulations, the 15 mm cutoff for intermediate suspicion, 25 mm cutoff for low suspicion and 
eliminating FNA for nodules of very low suspicion in the ATA guideline showed the highest specificity, accuracy 
and the lowest unnecessary biopsy  rate22. These results suggest that the high specificity and low unnecessary FNA 
rate of the ACR guideline was due to the larger size cutoff which is in line with our study  results22.
There are several limitations to this study. First, 1,244 of the 1,384 thyroid nodules (89.9%) were diagnosed 
based on cytologic findings alone, which could have resulted in some missed malignancies. We only included 
Figure 3.  Diagnostic performances of the four guidelines and their modified guidelines. The modified Kwak 
(mKwak), modified ATA (mATA) and modified EU (mEU) guidelines incorporated the size threshold suggested 
by the ACR guideline. ACR American College of  Radiology3, Kwak Kwak et al.’s  study8, ATA American Thyroid 
 Association7, EU European Thyroid  Association11.
Table 5.  Unnecessary Fine-needle Aspiration Rates. FNA Fine-Needle Aspiration, ACR American College 
of  Radiology3, Kwak Kwak et al.’s  study8, ATA American Thyroid  Association7, EU European Thyroid 
 Association11. *The modified Kwak (mKwak), modified ATA (mATA) and modified EU (mEU) guidelines 
incorporated the size threshold suggested by the ACR guideline.
Unnecessary FNA rate (%) No. of FNA nodules No. of test-negative nodules among FNA nodules
ACR guideline 63.8 647 413
Kwak guideline 72 987 711
mKwak guideline* 61.1 643 393
ATA guideline 75.3 1,163 876
mATA guideline* 65.3 717 468
EU guideline 73.9 1,063 786
mEU guideline* 70.6 928 655
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the nodules with definitive diagnostic cytopathologic findings (benign or malignant) at US-FNA, core needle 
biopsy, or surgery. Also, 5.2% (21/396) of the follicular carcinomas were diagnosed after surgery. Thus, a selection 
bias exists. Second, an experienced radiologist retrospectively re-assigned categories to thyroid nodules accord-
ing to different risk stratification systems using US features prospectively recorded by 14 radiologists who were 
familiar with point-scale risk stratification. When US descriptors were recorded in this study, they could not be 
defined with the exact same definitions used in the other original guidelines, an issue which was not considered 
during data analysis, and this might have led to differences in the final assessments made in real-time examina-
tions. Reassigning categories previously assigned according to the point-scale system to categories based on the 
pattern-recognition system might have also affected the results of this study. Third, the 14 radiologists perform-
ing the prospective imaging acquisition and analysis had variable levels of experience. Although interobserver 
variability and consistency are important considerations for choosing appropriate  guidelines27,28, our study is 
reflective of actual clinical practice. Forth, the relatively high malignancy rate of thyroid nodules in our study 
is probably because we only included thyroid nodules which underwent FNA, which would naturally lead to a 
higher number of malignant nodules. Also, our institution is a tertiary referral center and that itself is a reason 
for the high malignancy rate of the study population.
In conclusion, application of the larger US-FNA size threshold of the ACR guideline resulted in increased 
diagnostic accuracy and decreased unnecessary FNA rates at the expense of decreased sensitivity. The mKwak 
guideline which is practical and easy to use showed superior diagnostic accuracy than the other guidelines, 
both original and modified. Further longitudinal multicenter studies with larger data are needed in the future 
to choose an accurate and effective risk stratification system for daily practice.
Methods
The institutional review board (IRB) of the Yonsei University College of Medicine approved this retrospective 
study and the requirement for informed consent for review of images and medical records was waived. And all 
methods were performed in accordance with the Declaration of Helsinki.
Study cohort. This study was performed from December 2015 to November 2016, during which 2,179 
patients underwent US-FNA to diagnose thyroid nodules at our institution, a tertiary referral center. Among 
them, a total of 1704 thyroid nodules in 1602 patients were 10 mm or larger on US. 320 nodules were excluded 
because of a lack of definitive cytopathologic results after being initially diagnosed as nondiagnostic (n = 176), 
atypia or follicular lesion of undetermined significance (n = 110), follicular neoplasm or suspicion of follicular 
neoplasm (n = 27), or suspicion of malignancy (n = 7). Nodules were included if they had definitive diagnostic 
cytopathologic findings (benign or malignant) at US-FNA, core needle biopsy, or surgery. Finally, 1,384 thyroid 
nodules in 1,301 patients were included (Fig. 1).
Mean age of the 1,301 patients was 50.2 ± 13.6 years old (range 18–90 years). Mean size of the 1,384 thyroid 
nodules was 23.2 ± 12.6 mm (range 10-100 mm). Of the total patients, 1,062 (81.6%) were women and 239 
(18.4%) were men. Of the total patients, 77 had two nodules and three had three nodules.
US examinations. Thyroid US was performed with a 5–12  MHz linear array transducer (iU22; Philips 
Medical Systems). US examinations were performed by one of 14 board-certified radiologists (5 faculties and 9 
fellows) with 1–20 years of experience in thyroid imaging. US-FNAs were subsequently performed by the same 
radiologist who performed the thyroid US examination.
US features of thyroid nodules which underwent US-FNA were prospectively described and recorded in our 
institutional database at the time of US-FNA by the radiologist who performed the US and US-FNA accord-
ing to composition, echogenicity, margin, calcifications, and shape. The composition was classified as solid, 
predominantly solid, predominantly cyst, spongiform nodule and cyst, the echogenicity was classified as hyper-
echogenicity, isoechogenicity, hypoechogenicity and marked hypoechogenicity, the margin was classified as 
well-defined, microlobulated and irregular margin, the calcification was classified as negative, egg-shell calcifica-
tion, macrocalcification, microcalcification and mixed calcification. And the shape was classified as parallel and 
non-parallel. At our institution, US findings of solid composition, hypoechogenicity or marked hypoechogenicity, 
microlobulated or irregular margins, microcalcifications, and nonparallel shape were considered to be suspicious 
features for  malignancy29.
Data and statistical analysis. Cytopathology results from FNA and surgery were considered as the stand-
ard reference. One radiologist (J.Y.K) with 17  years of experience in thyroid imaging, blind to the patients’ 
clinical data and pathological results, retrospectively re-assigned the TIRADS categories of each thyroid nodule 
using our institutional database which was made up of data collected by the radiologists who performed the US-
FNAs. Ninety thyroid nodules (6.5%, 90/1,384) unspecified according to the ATA guideline including isoechoic 
or hyperechoic nodules with suspicious US  features7 were regarded as intermediate suspicion as the calculated 
malignancy rates of these nodules were within the range of 10–20%30.
Indications for FNA were based on US features and lesion size according to the various guidelines we used 
in this  study3,7,11. A size threshold of 10 mm was used to indicate US-FNA in all thyroid nodules with suspicious 
US features in the Kwak TIRADS because the Kwak TIRADS recommends US-FNA when thyroid nodules more 
than 10 mm in size have suspicious US features rather than applying different size thresholds according to the 
final assessment  category8,29. We applied the size criteria of the ACR TIRADS to the Kwak, ATA and EU guide-
lines according to similar recommended malignancy risk of each  category3,7,8,11, and defined the new guidelines 
as the mKwak, mATA and mEU guidelines, respectively (Supplementary Table S1 online). The ACR TIRADS 
recommends no FNA for not suspicious thyroid nodules with recommended risk of malignancy of 2%3. The same 
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strategy was applied for very low suspicion category of ATA guideline with recommended risk of malignancy 
of less than 3%7. For mildly suspicious thyroid nodules with a recommended malignancy risk of 5% in the ACR 
TIRADS, FNA was recommended when the nodule was 25 mm or  larger3. The same size threshold was applied 
for nodules of low risk according to the EU guideline rather than the present size threshold of 20 mm because the 
recommended risks of malignancy was 2–4%11. The recommended malignancy risk was 5–20% for moderately 
suspicious nodules in the ACR TIRADS and FNA was recommended when the nodule was 15 mm or  larger3. A 
size threshold of 15 mm was applied instead of 10 mm for nodules of intermediate suspicion according to the 
ATA guideline with a recommended malignancy risk of 10–20%7. We also used a size threshold proposed by the 
ACR TIRADS to the Kwak  guideline3,8: 25 mm size threshold for category 4a, 15 mm for category 4b and 10 mm 
for category 4c and 5. As the spongiform nodule and isolated macrocalcifications have no suspicious US feature 
according to Kwak TIRADS, they are considered as category  38.
Thyroid nodules were classified as nodules for which US-FNA was indicated and those for which it was not, 
according to the FNA criteria provided by each  guideline3,7,8,11.
To compare the demographics between benign and malignant nodules, the independent two sample t-test was 
used to compare continuous data including patient age and the Chi-square test was used to compare categorical 
data including patient sex. Since some patients had more than one nodule, the generalized estimated equation 
(GEE) was used to compare both continuous and categorical data between benign and malignant nodules. 
Malignancy rates according to the final assessment by each system were calculated and compared with GEE. 
We also evaluated diagnostic performances including sensitivity, specificity, accuracy, negative predictive value 
(NPV), positive predictive value (PPV), likelihood ratio (LR) and area under the receiver operating characteristic 
curve (AUC) along with 95% confidence intervals (CI). The sensitivity, specificity, accuracy, NPV, PPV and LR 
were compared with GEE. The Delong method was used to compare AUC. The unnecessary biopsy rate for the 
diagnosis of thyroid cancer was defined as the number of benign nodules among the biopsy-required nodules. 
Statistical analysis was performed with SAS software (version 9.4, SAS Inc.). A two-sided P < 0.05 was considered 
to indicate statistical significance.
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